These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22451133)

  • 21. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
    Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating real-world clinical practice in multiple sclerosis economic evaluations.
    McQueen RB; Nair KV; Vollmer TL; Campbell JD
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):869-72. PubMed ID: 26295727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia].
    Medina-Redondo F; Herrera-Carranza J; Sanabria C; Navarro G; García-Moreno JM; Gamero-García MA; Páramo MD; Ruiz-Peña JL; Izquierdo G
    Rev Neurol; 2004 Jul 1-15; 39(1):1-6. PubMed ID: 15257519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
    Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
    Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of burden and depression among caregivers of relapsing-remitting MS patients in Spain: MS Feeling study.
    Meca-Lallana J; Mendibe M; Hernández-Clares R; Caminero AB; Mallada-Frechin J; Dávila-Gonzalez P; Garcés-Redondo M; Gómez M; Millán-Pascual J; Soriano-Hernández G; Amigo-Jorrín Mdel C
    Neurodegener Dis Manag; 2016 Aug; 6(4):277-87. PubMed ID: 27480482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Tramacere I; Del Giovane C; Filippini G
    JAMA; 2016 Jan; 315(4):409-10. PubMed ID: 26813214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dimethyl fumarate (Tecfidera) for multiple sclerosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841
    [No Abstract]   [Full Text] [Related]  

  • 32. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.
    Tosh J; Dixon S; Carter A; Daley A; Petty J; Roalfe A; Sharrack B; Saxton JM
    Mult Scler; 2014 Jul; 20(8):1123-30. PubMed ID: 24421304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
    J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N; Tambour M; Henriksson F; Fredrikson S
    J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. US health insurance is an obstacle to disease-modifying treatments in MS.
    Bourdette D; Patti F
    Neurology; 2016 Jul; 87(4):346-7. PubMed ID: 27358336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.